Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q1 2023 Earnings Presentation
7 slides from Sanuwave Health's earnings presentation, May 12, 2023
Slide 1: Q1 2023 Update
Q1 2023 Update May 12, 2023 Kevin Richardson II
Slide 2: Access Information
2 Access Information Live Presentation Friday, May 12, 2023, 9:00 AM (EDT) Participant Dial-in Information Toll Free: 1-877-407-0784 Toll/International: 1-201-689-8560 OR click the Call me™ link for instant telephone access to the event. https://callme.viavid.com/viavid/?callme=true&passcode=1373236
Slide 3: Forward Looking Statements
3 Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the Company’s current views with respect to certain current and future events and financial performance. Forward-looking sta
Slide 4: Company Financials Q1 2023
4 Company Financials Q1 2023 Showing consistent topline growth while managing operating costs. (in millions) Q1 2022 Q1 2023 YoY Revenue $3.2 $3.8 + 18% Gross Profit $2.3 $2.5 + 9% Gross Margin 72% 67% -500bp Operating $4.3 $4.5 +5% Cost Revenue Gross Profit Operating Loss Operating ($2.0) ($2.0) -
Slide 5: Strong Unit Growth Continues
5 Strong Unit Growth Continues Strong Unit Growth throughout 2022 - Despite Supply Constraints 3/31/2022 6/30/2022 9/30/2022 12/31/2022 2022 Systems 25 64 43 85 217 Treatments 38,448 40,968 45,528 55,356 180,300 3/31/2023 6/30/2023 9/30/2023 12/31/2023 2023 Systems 28 Treatments 43,692
Slide 6: 2023 Q1 Revenue Guidance
6 2023 Q1 Revenue Guidance 2nd Quarter 2023 Q2 (estimate. +15 – 25% vs Q2 2022) Break Even Gross Margin Opex $1.8mm/mo 75% $1.4mm/mo Unbounded Upside: 1% market share in US wound market = $450 million
Slide 7: Summary
7 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for Patients, Payors, and Providers. SANUWAVE is in a prime position to benefit: § Approved products protected by strong IP § Strong existing reimbursement with room to impr